Direct Injection of Dilute Vasopressin To Facilitate Hysteroscopic Myomectomy with Mechanical Morcellators

Holloran-Schwartz, M.B.; Harrison, K.

doi:10.1016/j.jmig.2012.08.605

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…have concluded that during hysteroscopic myomectomy, injecting a diluted vasopressin solution into a submucosal myoma can provide the surgeon with more hemostasis and visualization in order to perform complete resection. [ 18 ]…”

Section: Discussionmentioning

confidence: 99%

The Effect of Vasopressin during Hysteroscopic Myomectomy in Patients with Submucosal Myoma

Rouholamin

Hashemi

Haghshenas

2021

Advanced Biomedical Research

View full text Add to dashboard Cite

Background: The aim was to assess the effect of vasopressin in reducing the time of surgery, amount of bleeding, and fluid deficit during hysteroscopic myomectomy of submucosal myoma from 2016 to 2018. Materials and methods: This study was conducted as a prospective, randomized, single-blinded clinical trial on the premenopausal women ranged from 18 to 62 years' old. A number of 80 patients were randomly assigned to each arm of the study according to random consecutive numbers. The control group ( n = 40) of patients underwent conventional hysteroscopic myomectomy without vasopressin and the case group ( n = 40) underwent hysteroscopic myomectomy with the injection of diluted vasopressin. Measured outcomes were time for myomectomy, fluid deficit, inflow volume, visual clarity, and postoperation hemoglobin level. Results: The mean time of myomectomy was 38.1 and 77.38 min in vasopressin and control groups, respectively ( P < 0.001). The mean inflow volume was 2800 and 4100 in vasopressin and control groups, respectively ( P = 0.029). The visual clarity score was 8.5 and 6.5 in the vasopressin and control groups, respectively ( P < 0.001). Conclusions: The injection of vasopressin during hysteroscopic myomectomy is effective in the management of fluid deficit, time of surgery, and improvement of visual clarity.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of Vasopressin during Hysteroscopic Myomectomy in Patients with Submucosal Myoma

Rouholamin

Hashemi

Haghshenas

2021

Advanced Biomedical Research

View full text Add to dashboard Cite

show abstract

“…The success of hysteroscopic surgical procedures is strongly dependent on constant surgical field visibility, so implementing the best strategy to decrease intraoperative blood loss remains a research priority. Injecting a dilute vasopressin solution directly into the submucosal myoma [26,31], intracervical administration of vasopressin [32], gonadotropin-releasing hormone agonist, danazol [2,33], epsilon-aminocaproic acid (EACA), or oxytocin [30] all have different mechanisms of actions, variable effects, costs, and side effects.…”

Section: Discussionmentioning

confidence: 99%

Intrauterine Instillation of Tranexamic Acid in Hysteroscopic Myomectomy: A Double-Blind, Placebo-Controlled, Parallel-Group Randomized Clinical Trial

Rasheedy

Makled

Abou-Gamrah

et al. 2020

Journal of Minimally Invasive Gynecology

View full text Add to dashboard Cite

Direct Injection of Dilute Vasopressin To Facilitate Hysteroscopic Myomectomy with Mechanical Morcellators

Cited by 2 publications

References 0 publications

The Effect of Vasopressin during Hysteroscopic Myomectomy in Patients with Submucosal Myoma

The Effect of Vasopressin during Hysteroscopic Myomectomy in Patients with Submucosal Myoma

Intrauterine Instillation of Tranexamic Acid in Hysteroscopic Myomectomy: A Double-Blind, Placebo-Controlled, Parallel-Group Randomized Clinical Trial

Contact Info

Product

Resources

About